Hence there is only half of the KIT/PDGFRA WT GIST that are recognized as either SDH-deficient or BRAF/RAS/NF1 mutated, but still the other half remains orphan of a driver oncogenic event and possibly of a specific target for therapy. This evidence concerns the gene KIT and gastrointestinal stromal tumor.